Allworth Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Allworth Financial’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300	Closed	-$792	–	5213
2025 Q3	$792	Hold	300	–	–	﹤0.01%	4316
2025 Q2	$675	Buy	+300	New	+$662	﹤0.01%	4063

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Aquamarine Financial George Town $1.37B AUM

SCM

SB Capital Management Encino, California $273M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allworth Financial's ORMP Position: Q4 2025 in Review

Allworth Financial sold out of Oramed Pharmaceuticals (ORMP) in Q4 2025, closing a stake of 300 shares — an estimated $792 sold.

Allworth Financial first reported a position in ORMP in Q2 2025 and held it in 2 quarters. The position peaked at $792 in Q3 2025. 57 funds tracked by Wall St. Rank hold ORMP as of Q4 2025.

Allworth Financial reported no remaining Oramed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Allworth Financial sold 300 Oramed Pharmaceuticals shares in Q4 2025, an estimated $792.
Allworth Financial first reported a position in Oramed Pharmaceuticals in Q2 2025 and held it in 2 quarters.
Allworth Financial's Oramed Pharmaceuticals position peaked at $792 in Q3 2025.
57 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2025.

Based on Allworth Financial's 13F filing for Q4 2025, filed 5 Feb 2026.